Anxiety, depression, and insomnia are three of the most prevalent issues faced in our day and age.
The first line of defense has traditionally been pharmaceutical medications, but drug therapy shows to have only a modest efficacy and often come with quite a lot of side effects.
Fisher Wallace Laboratories has developed a wearable medical device that is showing much better results in comparison to standard drug therapy and with virtually no side effects.
In just 20 minutes a day, the Fisher Wallace Stimulator provides gentle stimulation to the brain which results in the natural production of serotonin while also helping to modulate brainwave activity.
The Future of Fisher Wallace Laboratories
Having received authorization from the FDA to conduct three clinical trials in 2019, Fisher Wallace is hoping to use the results of these studies to obtain FDA approval for their device to be covered by insurance.
This will skyrocket the scale at which Fisher Wallace’s can go to market because it will reduce the barrier to entry that currently exists because users must pay the full market price of the device out of pocket.
Yet despite this limitation, the Fisher Wallace Stimulator has been used by over 60k patients in the US alone.
What Interested Investors Need to Know
Three things that investors should take note of:
- On track towards FDA Approval: The success their clinical trials have shown thus far means they are well on their way to receiving full FDA Approval.
- Innovation: In a world where pharmaceuticals are the standard mode of action, there is a lot of room for an innovative approach.
- No side effects: Less than 1% of participants experience any form of side effects.